OraSure Technologies (NASDAQ:OSUR) Director Buys $74,500.00 in Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director Steven Kyle Boyd acquired 25,000 shares of the stock in a transaction on Tuesday, May 12th. The shares were bought at an average price of $2.98 per share, for a total transaction of $74,500.00. Following the purchase, the director owned 63,462 shares in the company, valued at approximately $189,116.76. This trade represents a 65.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Steven Kyle Boyd also recently made the following trade(s):

• On Thursday, May 14th, Steven Kyle Boyd bought 25,000 shares of OraSure Technologies stock. The shares were bought at an average price of $2.99 per share, with a total value of $74,750.00.

OraSure Technologies Stock Down 3.0%

Shares of OSUR traded down $0.09 during trading hours on Thursday, hitting $2.95. 868,088 shares of the company were exchanged, compared to its average volume of 535,873. OraSure Technologies, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $3.82. The company has a market cap of $203.11 million, a price-to-earnings ratio of -2.84 and a beta of 0.89. The firm’s fifty day moving average is $3.06 and its 200 day moving average is $2.76.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The firm had revenue of $26.76 million for the quarter, compared to the consensus estimate of $26.44 million. OraSure Technologies had a negative return on equity of 18.57% and a negative net margin of 66.42%.

Hedge Funds Weigh In On OraSure Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kotler Kevin bought a new stake in shares of OraSure Technologies during the fourth quarter worth $4,359,000. Altai Capital Management L.P. lifted its stake in shares of OraSure Technologies by 73.4% in the 3rd quarter. Altai Capital Management L.P. now owns 3,748,836 shares of the medical instruments supplier’s stock valued at $12,034,000 after acquiring an additional 1,586,488 shares during the last quarter. Millennium Management LLC lifted its stake in shares of OraSure Technologies by 71.1% in the 3rd quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock valued at $6,781,000 after acquiring an additional 878,151 shares during the last quarter. Yorkville Advisors Global LP acquired a new stake in shares of OraSure Technologies during the first quarter valued at about $1,905,000. Finally, Archon Capital Management LLC acquired a new stake in OraSure Technologies during the 4th quarter worth approximately $1,388,000. Institutional investors own 93.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 7th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.